High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: A Cancer and Leukemia Group B (CALGB) study

Blood

Volumn 111, Issue 11, 2008, Pages 5371-5379

  Langer, Christian ^a,b   Radmacher, Michael D ^a,c   Ruppert, Amy S ^a,c   Whitman, Susan P ^a   Paschka, Peter ^a   Mrózek, Krzysztof ^a   Baldus, Claudia D ^d   Vukosavljevic, Tamara ^a   Liu, Chang Gong ^b   Ross, Mary E ^e   Powell, Bayard L ^f   De La Chapelle, Albert ^b   Kolitz, Jonathan E ^g   Larson, Richard A ^h   Marcucci, Guido ^a,b   Bloomfield, Clara D ^a,b  

^a Department of Medicine   (Germany)

^b OHIO STATE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^f WAKE FOREST BAPTIST HEALTH   (United States)

^g NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; COMPLEMENTARY DNA; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MESSENGER RNA; MICRORNA; MOLECULAR MARKER; VALSPODAR; ANTINEOPLASTIC AGENT; BAALC PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BAALC GENE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; STEM CELL MOBILIZATION; TREATMENT OUTCOME; BIOSYNTHESIS; CLINICAL TRIAL; DNA MICROARRAY; GENE EXPRESSION PROFILING; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, ACUTE; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 45949110015     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-124958     Document Type: Article

References (61)

1. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336.
2. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312-1320.
3. Mrózek K, Heerema NA, Bloomfield GD. Cytogenetics in acute leukemia. Blood. Rev. 2004;18: 115-136.
4. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res. 2001 ;61:7233-7239.
5. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100: 4372-4380.
6. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005; 352:254-266.
7. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740- 3746.
8. Verhaak RGW, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106: 3747-3754.
9. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005; 106:3733- 3739.
10. Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22:624-633.
11. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100:2717-2723.
12. Fröhling S, Dohner H. Disruption of C/EBPα function in acute myeloid leukemia. N Engl J Med. 2004;351:2370-2372.
13. Caligiuri MA, St rout M P, Lawrence D, et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res. 1998; 58:55-59.
14. Dohner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol. 2002;20:3254-3261.
15. Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:9234-9242.
16. Marcucci G, Maharry K, Whitman SP, et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2007;25:3337-3343.
17. Tanner SM, Austin JL, Leone G, et al. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoi- esis and acute leukemia. Proc Natl Acad Sci U S A. 2001:98:13901-13906.
18. Baldus CD. Tanner SM. RuppertAS. et al. BAALCexpression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood. 2003;102:1613-1618.
19. Satoskar AA, Tanner SM, Weinstein M, Qualman SJ, de la Chapelle A. Baaic, a marker of mesoderm and muscle. Gene Expr Patterns. 2005;5: 463-473.
20. 2+/ calmodulin-dependent protein kinase II. J Neurochem. 2005;92:647-659.
21. Baldus CD, Tanner SM, Kusewitt DF, et al. BAALC, a novel marker of human hematopoietic progenitor cells. Exp Hematol. 2003;31:1051 - 1056.
22. Bienz M, Ludwig M, Oppliger Leibundgut E, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype [Erratum in: Clin Cancer Res. 2005;11:5659]. Clin Cancer Res. 2005;11:1416-1424.
23. Baldus CD, Thiede C, Soucek S, Bloomfield CD, Thiel E, Ehninger G. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol. 2006;24:790-797.
24. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109:431-448.
25. Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B study 9621. J Clin Oncol. 2004;22:4290- 4301.
26. Kolitz JE, George SL, Marcucci G, et al. A randomized comparison of induction therapy for untreated acute myeloid leukemia (AML) in patients < 60 years using P-glycoprotein (Pgp) modulation with Valspodar (PSC833): preliminary results of Gancer and Leukemia Group B study 19808 [abstract]. Blood. 2005;106:122a-123a. Abstract 407.
27. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-4335.
28. Whitman SP, Liu S, Vukosavljevic T, et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood. 2005;106:345- 352.
29. Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene- expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008;111:1552-1559.
30. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434-2439.
31. Calin GA, Ferracin M, Cimmino A, et al. Ami- croRNA signature associated with prognosis and progression in chronic lymphocytic leukemia [Erratum in: N Engl J Med. 2006;355:533]. N Engl J Med. 2005;353:1793-1801.
32. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York, NY: Springer-Verlag; 1997.
33. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res (http://nar. oxfordjournals.org/). 2003;31 :e15.
34. Memorial Sloan-Kettering Gancer Center. The microRNA.org resource: targets and expression. http://www.microrna.org/. Accessed October 28, 2007.
35. Whitehead Institute for Biomedical Research. Target Scan, http://www.targetscan.org/. Accessed October 28, 2007.
36. Sanger Institute. miRBase http://microrna.sanger.ac.uk/. Accessed October 28, 2007.
37. + cells. Stem Cells. 2006; 24:631-641.
38. Toren A, Bielorai B, Jacob-Hirsch J, et al. CD133- positive hematopoietic stem cell '"sternness" genes contain many genes mutated or abnormally expressed in leukemia. Stem Cells. 2005; 23:1142-1153.
39. Kim JG, Sohn SK, Kim DH, et al. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma. 2005;46:885-891.
40. Verstovsek S, Kantarjian H, Estey E, et al. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia. 2001 ;15:1165-1170.
41. Heuser M, Beutel G, Krauter J, et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood. 2006;108:3898-3905.
42. 42.Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukaemia [letter]. Leukemia. 2007;21:566-568.
43. Pirker R, Wallner J, Geissler K, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst. 1991 ;83:708- 712.
44. Campos L, Guyotat D.Archimbaud E, et al. Clinical significance of multidrug resistance P- glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood. 1992;79:473-476.
45. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group study. Blood. 1997; 89:3323-3329.
46. Samdani A, Vijapurkar U, Grimm MA, et al. Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leuk Res. 1996;20:175- 180.
47. Leith CP, Kopecky KJ, Chen l-M, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P- glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study. Blood. 1999;94:1086-1099.
48. Schaich M, Soucek S, Thiede C, Ehninger G, lllmer T. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol. 2005:128:324-332.
49. Wuchter C, Leonid K, Ruppert V, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica. 2000;85:711-721.
50. Chen Y-T, Scanlan MJ, Venditti CA, et al. Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc Natl Acad Sci USA. 2005;102:7940-7945.
51. Heidebrecht HJ, Claviez A, Kruse ML, et al. Characterization and expression of CT45 in Hodgkin's lymphoma. Clin Cancer Res. 2006;12:4804-4811.
52. Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood. 2004; 104:1940-1951.
53. Heuser M, Wingen LU, Steinemann D, et al. Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. Haematologica. 2005;90:1484-1492.
54. Georgantas RW III. Tanadve V, Malehorn M, et al. Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res. 2004;64:4434-4441.
55. Wagner W, Ansorge A, Wirkner U, et al. Molecular evidence for stem cell function of the slow- dividing fraction among human hematopoietic progenitor cells by genome-wide analysis. Blood. 2004;104:675-686.
56. - hematopoietic stem cells using cell surface markers AC133 and CD7. Blood. 2000;95:2813-2820.
57. Bhatia M. AC133 expression in human stem cells. Leukemia. 2001 ;15:1685-1688.
58. Bene MC, Castoldi G, Knapp W, et al. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 2004;18:394-400.
59. Bartel DR MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281 - 297.
60. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189- 198.
61. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297: 1901-1908.